Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.34 |
| ▸ | GNPAT | O15228 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23743653 | 0.85 | KISS1R (0.36) | — | |
| SCHEMBL20032178 | 0.81 | NOD1 (0.40) | GGT1FOLH1NOD1GNPAT | |
| SCHEMBL20227446 | 0.81 | NOD1 (0.40) | GGT1FOLH1NOD1GNPAT | |
| SCHEMBL22100977 | 0.80 | KISS1R (0.44) | FOLH1MEN1GAAKMT2ANOD1 | |
| SCHEMBL161213 | 0.80 | FOLH1 (0.49) | GGT1FOLH1NOD1GNPATGABRR1 | |
| SCHEMBL569594 | 0.80 | FOLH1 (0.49) | GGT1FOLH1NOD1GNPATGABRR1 | |
| SCHEMBL12890791 | 0.80 | KISS1R (0.44) | FOLH1MEN1GAAKMT2ANOD1 | |
| SCHEMBL13323375 | 0.80 | KISS1R (0.44) | FOLH1MEN1GAAKMT2ANOD1 | |
| SCHEMBL161214 | 0.80 | FOLH1 (0.49) | GGT1FOLH1NOD1GNPATGABRR1 | |
| SCHEMBL164121 | 0.79 | FOLH1 (0.56) | FOLH1GABRR1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450275-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | GGT1 1378/4885FOLH1 878/4885MEN1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.